Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy: JCO flashback
PURPOSE - To compare the efficacy and toxicity of pemetrexed versus docetaxel in patients with advanced non-small-cell lung cancer (NSCLC) previously treated with chemotherapy. - PATIENTS AND METHODS - Eligible patients had a performance status 0 to 2, previous treatment with one prior chemotherapy...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
May 17, 2023
|
| In: |
Journal of clinical oncology
Year: 2023, Jahrgang: 41, Heft: 15, Pages: 2682-2690 |
| ISSN: | 1527-7755 |
| DOI: | 10.1200/JCO.22.02546 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1200/JCO.22.02546 Verlag, lizenzpflichtig, Volltext: https://ascopubs.org/doi/abs/10.1200/JCO.22.02546 
|
| Verfasserangaben: | Nasser Hanna, Frances A. Shepherd, Frank V. Fossella, Jose R. Pereira, Filippo De Marinis, Joachim von Pawel, Ulrich Gatzemeier, Thomas Chang Yao Tsao, Miklos Pless, Thomas Muller, Hong-Liang Lim, Christopher Desch, Klara Szondy, Radj Gervais, Shaharyar, Christian Manegold, Sofia Paul, Paolo Paoletti, Lawrence Einhorn, and Paul A. Bunn, Jr. |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1858210984 | ||
| 003 | DE-627 | ||
| 005 | 20240307055212.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230829s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1200/JCO.22.02546 |2 doi | |
| 035 | |a (DE-627)1858210984 | ||
| 035 | |a (DE-599)KXP1858210984 | ||
| 035 | |a (OCoLC)1425212498 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 245 | 0 | 0 | |a Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy |b JCO flashback |c Nasser Hanna, Frances A. Shepherd, Frank V. Fossella, Jose R. Pereira, Filippo De Marinis, Joachim von Pawel, Ulrich Gatzemeier, Thomas Chang Yao Tsao, Miklos Pless, Thomas Muller, Hong-Liang Lim, Christopher Desch, Klara Szondy, Radj Gervais, Shaharyar, Christian Manegold, Sofia Paul, Paolo Paoletti, Lawrence Einhorn, and Paul A. Bunn, Jr. |
| 264 | 1 | |c May 17, 2023 | |
| 264 | 4 | |c © 2004 | |
| 300 | |a 9 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 29.08.2023 | ||
| 500 | |a This article is a republication of jco.2004.08.163 | ||
| 520 | |a PURPOSE - To compare the efficacy and toxicity of pemetrexed versus docetaxel in patients with advanced non-small-cell lung cancer (NSCLC) previously treated with chemotherapy. - PATIENTS AND METHODS - Eligible patients had a performance status 0 to 2, previous treatment with one prior chemotherapy regimen for advanced NSCLC, and adequate organ function. Patients received pemetrexed 500 mg/m2 intravenously (IV) day 1 with vitamin B12, folic acid, and dexamethasone or docetaxel 75 mg/m2 IV day 1 with dexamethasone every 21 days. The primary end point was overall survival. - RESULTS - Five hundred seventy-one patients were randomly assigned. Overall response rates were 9.1% and 8.8% (analysis of variance P = .105) for pemetrexed and docetaxel, respectively. Median progression-free survival was 2.9 months for each arm, and median survival time was 8.3 versus 7.9 months (P = not significant) for pemetrexed and docetaxel, respectively. The 1-year survival rate for each arm was 29.7%. Patients receiving docetaxel were more likely to have grade 3 or 4 neutropenia (40.2% v 5.3%; P < .001), febrile neutropenia (12.7% v 1.9%; P < .001), neutropenia with infections (3.3% v 0.0%; P = .004), hospitalizations for neutropenic fever (13.4% v 1.5%; P < .001), hospitalizations due to other drug related adverse events (10.5% v 6.4%; P = .092), use of granulocyte colony-stimulating factor support (19.2% v 2.6%, P < .001) and all grade alopecia (37.7% v 6.4%; P < .001) compared with patients receiving pemetrexed. - CONCLUSION - Treatment with pemetrexed resulted in clinically equivalent efficacy outcomes, but with significantly fewer side effects compared with docetaxel in the second-line treatment of patients with advanced NSCLC and should be considered a standard treatment option for second-line NSCLC when available. | ||
| 700 | 1 | |a Hanna, Nasser |e VerfasserIn |0 (DE-588)1300406836 |0 (DE-627)1858211093 |4 aut | |
| 700 | 1 | |a Shepherd, Frances A. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Fossella, Frank V. |e VerfasserIn |0 (DE-588)173569633 |0 (DE-627)698480554 |0 (DE-576)134413598 |4 aut | |
| 700 | 1 | |a Pereira, Jose R. |e VerfasserIn |4 aut | |
| 700 | 1 | |a De Marinis, Filippo |e VerfasserIn |4 aut | |
| 700 | 1 | |a Pawel, Joachim von |d 1950- |e VerfasserIn |0 (DE-588)109734882 |0 (DE-627)623684233 |0 (DE-576)321402103 |4 aut | |
| 700 | 1 | |a Gatzemeier, Ulrich |e VerfasserIn |0 (DE-588)172663172 |0 (DE-627)697596648 |0 (DE-576)133521672 |4 aut | |
| 700 | 1 | |a Tsao, Thomas Chang Yao |e VerfasserIn |4 aut | |
| 700 | 1 | |a Pless, Miklos |e VerfasserIn |0 (DE-588)1201832292 |0 (DE-627)168598391X |4 aut | |
| 700 | 1 | |a Muller, Thomas |e VerfasserIn |4 aut | |
| 700 | 1 | |a Lim, Hong-Liang |e VerfasserIn |4 aut | |
| 700 | 1 | |a Desch, Christopher |e VerfasserIn |4 aut | |
| 700 | 1 | |a Szondy, Klara |e VerfasserIn |4 aut | |
| 700 | 1 | |a Gervais, Radj |e VerfasserIn |4 aut | |
| 700 | 1 | |a Shaharyar, Shaharyar |e VerfasserIn |4 aut | |
| 700 | 1 | |a Manegold, Christian |d 1946-2022 |e VerfasserIn |0 (DE-588)108614913 |0 (DE-627)490287360 |0 (DE-576)289617200 |4 aut | |
| 700 | 1 | |a Paul, Sofia |e VerfasserIn |4 aut | |
| 700 | 1 | |a Paoletti, Paolo |e VerfasserIn |4 aut | |
| 700 | 1 | |a Einhorn, Lawrence |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bunn, Paul A. |e VerfasserIn |0 (DE-588)112923437 |0 (DE-627)691165505 |0 (DE-576)309532515 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of clinical oncology |d Alexandria, Va. : American Society of Clinical Oncology, 1983 |g 41(2023), 15 vom: Mai, Seite 2682-2690 |h Online-Ressource |w (DE-627)313116962 |w (DE-600)2005181-5 |w (DE-576)090887018 |x 1527-7755 |7 nnas |a Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy JCO flashback |
| 773 | 1 | 8 | |g volume:41 |g year:2023 |g number:15 |g month:05 |g pages:2682-2690 |g extent:9 |a Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy JCO flashback |
| 856 | 4 | 0 | |u https://doi.org/10.1200/JCO.22.02546 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://ascopubs.org/doi/abs/10.1200/JCO.22.02546 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20230829 | ||
| 993 | |a Article | ||
| 994 | |a 2023 | ||
| 998 | |g 108614913 |a Manegold, Christian |m 108614913:Manegold, Christian |d 60000 |e 60000PM108614913 |k 0/60000/ |p 16 | ||
| 999 | |a KXP-PPN1858210984 |e 4370909066 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"title":[{"subtitle":"JCO flashback","title":"Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy","title_sort":"Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy"}],"person":[{"family":"Hanna","given":"Nasser","roleDisplay":"VerfasserIn","display":"Hanna, Nasser","role":"aut"},{"display":"Shepherd, Frances A.","roleDisplay":"VerfasserIn","role":"aut","family":"Shepherd","given":"Frances A."},{"family":"Fossella","given":"Frank V.","display":"Fossella, Frank V.","roleDisplay":"VerfasserIn","role":"aut"},{"given":"Jose R.","family":"Pereira","role":"aut","roleDisplay":"VerfasserIn","display":"Pereira, Jose R."},{"family":"De Marinis","given":"Filippo","roleDisplay":"VerfasserIn","display":"De Marinis, Filippo","role":"aut"},{"role":"aut","display":"Pawel, Joachim von","roleDisplay":"VerfasserIn","given":"Joachim von","family":"Pawel"},{"roleDisplay":"VerfasserIn","display":"Gatzemeier, Ulrich","role":"aut","family":"Gatzemeier","given":"Ulrich"},{"given":"Thomas Chang Yao","family":"Tsao","role":"aut","display":"Tsao, Thomas Chang Yao","roleDisplay":"VerfasserIn"},{"given":"Miklos","family":"Pless","role":"aut","display":"Pless, Miklos","roleDisplay":"VerfasserIn"},{"given":"Thomas","family":"Muller","role":"aut","roleDisplay":"VerfasserIn","display":"Muller, Thomas"},{"display":"Lim, Hong-Liang","roleDisplay":"VerfasserIn","role":"aut","family":"Lim","given":"Hong-Liang"},{"roleDisplay":"VerfasserIn","display":"Desch, Christopher","role":"aut","family":"Desch","given":"Christopher"},{"family":"Szondy","given":"Klara","display":"Szondy, Klara","roleDisplay":"VerfasserIn","role":"aut"},{"family":"Gervais","given":"Radj","roleDisplay":"VerfasserIn","display":"Gervais, Radj","role":"aut"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Shaharyar, Shaharyar","given":"Shaharyar","family":"Shaharyar"},{"family":"Manegold","given":"Christian","roleDisplay":"VerfasserIn","display":"Manegold, Christian","role":"aut"},{"display":"Paul, Sofia","roleDisplay":"VerfasserIn","role":"aut","family":"Paul","given":"Sofia"},{"given":"Paolo","family":"Paoletti","role":"aut","roleDisplay":"VerfasserIn","display":"Paoletti, Paolo"},{"family":"Einhorn","given":"Lawrence","display":"Einhorn, Lawrence","roleDisplay":"VerfasserIn","role":"aut"},{"display":"Bunn, Paul A.","roleDisplay":"VerfasserIn","role":"aut","family":"Bunn","given":"Paul A."}],"language":["eng"],"recId":"1858210984","type":{"bibl":"article-journal","media":"Online-Ressource"},"note":["Gesehen am 29.08.2023","This article is a republication of jco.2004.08.163"],"id":{"doi":["10.1200/JCO.22.02546"],"eki":["1858210984"]},"origin":[{"dateIssuedDisp":"May 17, 2023","dateIssuedKey":"2023"}],"name":{"displayForm":["Nasser Hanna, Frances A. Shepherd, Frank V. Fossella, Jose R. Pereira, Filippo De Marinis, Joachim von Pawel, Ulrich Gatzemeier, Thomas Chang Yao Tsao, Miklos Pless, Thomas Muller, Hong-Liang Lim, Christopher Desch, Klara Szondy, Radj Gervais, Shaharyar, Christian Manegold, Sofia Paul, Paolo Paoletti, Lawrence Einhorn, and Paul A. Bunn, Jr."]},"relHost":[{"note":["Fortsetzung der Druck-Ausgabe","Gesehen am 22.05.23"],"disp":"Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy JCO flashbackJournal of clinical oncology","type":{"bibl":"periodical","media":"Online-Ressource"},"recId":"313116962","language":["eng"],"corporate":[{"roleDisplay":"Herausgebendes Organ","display":"American Society of Clinical Oncology","role":"isb"}],"pubHistory":["1.1983 -"],"part":{"year":"2023","pages":"2682-2690","issue":"15","text":"41(2023), 15 vom: Mai, Seite 2682-2690","volume":"41","extent":"9"},"titleAlt":[{"title":"official journal of the American Society of Clinical Oncology"},{"title":"JCO"},{"title":"Journal of clinical oncology legacy archive (ASCO)"}],"title":[{"subtitle":"JCO : an American Society of Clinical Oncology journal","title":"Journal of clinical oncology","title_sort":"Journal of clinical oncology"}],"physDesc":[{"extent":"Online-Ressource"}],"origin":[{"dateIssuedDisp":"1983-","publisher":"American Society of Clinical Oncology ; Lippincott Williams & Wilkins","dateIssuedKey":"1983","publisherPlace":"Alexandria, Va. ; Baltimore, Md. [u.a.]"}],"id":{"eki":["313116962"],"zdb":["2005181-5"],"issn":["1527-7755"]}}],"physDesc":[{"extent":"9 S."}]} | ||
| SRT | |a HANNANASSERANDOMIZED1720 | ||